Group 1 - The stock of Saikexide (688338.SH) closed at 32.55 yuan, with a decline of 2.11%, currently in a state of breaking issue [1] - Saikexide was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 6, 2020, with an initial issuance of 20.41 million shares at a price of 50.35 yuan per share [1] - On its first trading day, Saikexide opened at 180.00 yuan and closed at 170.18 yuan, reaching an intraday high of 186.00 yuan, which remains the highest price since its listing [1] - The total amount of funds raised by Saikexide was 1.028 billion yuan, with a net amount of 924 million yuan after deducting issuance costs, exceeding the original plan by 554 million yuan [1] - The company planned to raise 371 million yuan for projects including production base construction, R&D center construction, marketing network construction, and working capital supplementation [1] - The sponsor institution for Saikexide is China International Capital Corporation (CICC), with representatives Fang Liangrun and Xu Shiyan [1] - The total issuance cost for the initial public offering was 103 million yuan, with CICC receiving 85.322 million yuan in sponsorship and underwriting fees [1] Group 2 - The wholly-owned subsidiary of the sponsor institution, China CICC Wealth Securities Co., Ltd., was allocated 816,480 shares, amounting to 41,109,768 yuan, accounting for 4% of the total shares issued [2] - The lock-up period for the allocated shares is 24 months from the date of listing on the Shanghai Stock Exchange [2] - On July 1, 2023, Saikexide announced its 2022 annual equity distribution plan, which includes a cash dividend of 0.26 yuan per share (tax included) and a capital reserve increase of 0.3 shares per share for all shareholders [2] - The record date for the equity distribution is July 6, 2023, and the ex-dividend date is July 7, 2023 [2]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Group 1 - The core viewpoint of the news is that Saikexide's stock has experienced a significant increase, with a 5.1% rise on February 6, reaching a price of 34.59 yuan per share, and a total market capitalization of 3.671 billion yuan [1] - Saikexide has seen a cumulative increase of 15.55% over the past three days, indicating strong market performance [1] - The company specializes in the research, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis, with its main revenue sources being reagents (53.71%), instruments (25.40%), and consumables (20.58%) [1] Group 2 - Qianhai Kaiyuan Fund holds a significant position in Saikexide, with its Event-Driven Mixed A Fund (000423) owning 134,100 shares, accounting for 4.77% of the fund's net value, making it the third-largest holding [2] - The fund has realized a floating profit of approximately 225,300 yuan today, and a total of 594,200 yuan during the three-day increase [2] - The fund has shown a year-to-date return of 8.42% and a one-year return of 32.69%, ranking 1299 out of 8873 and 3522 out of 8123 in its category, respectively [2]

Market Overview - The medical device sector increased by 0.9% on February 4, with SAIKOSHI leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Performers - SAIKOSHI (688338) closed at 32.11, up 10.15% with a trading volume of 63,600 shares and a transaction value of 197 million [1] - SHUOSHI BIO (6638889) closed at 71.46, up 5.69% with a trading volume of 15,900 shares and a transaction value of 113 million [1] - BAOLAIT (300246) closed at 13.51, up 2.74% with a trading volume of 166,100 shares and a transaction value of 224 million [1] Underperformers - KANGZHONG MEDICAL (688607) closed at 57.80, down 4.26% with a trading volume of 46,300 shares [2] - SINO MEDICAL (688108) closed at 22.70, down 3.77% with a trading volume of 170,600 shares and a transaction value of 387 million [2] - SANYOU MEDICAL (688085) closed at 21.05, down 3.08% with a trading volume of 39,800 shares and a transaction value of 84 million [2] Capital Flow - The medical device sector experienced a net outflow of 132 million from institutional investors, while retail investors saw a net outflow of 191 million [2] - Speculative funds had a net inflow of 323 million into the sector [2] Individual Stock Capital Flow - MAIRUI MEDICAL (300760) had a net inflow of 86.91 million from institutional investors, while retail investors had a net outflow of 169 million [3] - LIANSHENG MEDICAL (688271) saw a net inflow of 44.32 million from institutional investors, with a net outflow of 76.86 million from retail investors [3] - HUAKANG CLEAN (301235) had a net inflow of 31.25 million from institutional investors, while retail investors experienced a net outflow of 52.92 million [3]

Core Viewpoint - The company Sikehde (688338) is experiencing a decline in financial performance, primarily due to the impact of medical insurance cost control policies on the in vitro diagnostic industry, leading to reduced market demand and a significant drop in reagent revenue [1][3]. Financial Performance Summary - As of January 30, 2026, Sikehde's stock closed at 29.04 yuan, up 0.17% from the previous week, with a market capitalization of 3.082 billion yuan [1]. - The company is set to release its 2025 annual report, with a preliminary report indicating a net profit attributable to shareholders of 87.14 million yuan, a year-on-year decrease of 22.88% [1][3]. - Total operating revenue for 2025 is reported at 263.67 million yuan, reflecting a year-on-year decline of 13.80% [1][3]. - The net profit after deducting non-recurring gains and losses decreased by 26.31% year-on-year [1][3]. - Total assets increased by 0.99% compared to the beginning of the period, while equity attributable to shareholders grew by 2.50% [1][3].

（文章来源：证券日报） 证券日报网讯 1月28日，赛科希德发布公告称，公司2025年实现营业收入263，667，956.92元，同比下 降13.80%；归属于母公司所有者的净利润87，143，189.53元，同比下降22.88%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑;主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 智通财经APP讯，赛科希德(688338.SH)发布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%;实现归属于母公司所有者的净利润8714.3万元，同比下降22.88%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...

报告期内，公司所处的体外诊断行业受到医保控费等行业政策影响，国内市场需求减少、价格承压。受 以上因素影响，公司营业收入出现了小幅下滑；主营业务收入尤其试剂收入的下降，导致净利润降幅略 大于营业收入降幅。 格隆汇1月28日丨赛科希德(688338.SH)公布2025年度业绩快报，报告期内，公司实现营业收入2.64亿 元，同比下降13.80%；实现归属于母公司所有者的净利润8714.32万元，同比下降22.88%；实现归属于 母公司所有者的扣除非经常性损益的净利润8141.81万元，同比下降26.31%。 ...

| | | | 单位：人民币元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅 | | | | | 度（％） | | 营业总收入 | 263,667,956.92 | 305,870,242.02 | -13.80 | | 营业利润 | 103,182,223.44 | 129,959,557.54 | -20.60 | | 利润总额 | 102,760,877.72 | 129,801,510.50 | -20.83 | | 归属于母公司所有者的净利 润 | 87,143,189.53 | 112,999,583.01 | -22.88 | | 归属于母公司所有者的扣除 | 81,418,076.22 | 110,486,685.01 | -26.31 | | 非经常性损益的净利润 | | | | | 基本每股收益（元） | 0.84 | 1.07 | -21.50 | | 加权平均净资产收益率 | 5.24% | 6.91% | 减少 1.67 个 | | | | | 百分点 | | | 本报告期末 | 本报告期初 | 增减变动幅 | | | ...